Apogee Therapeutics (APGE) Non Operating Income (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Non Operating Income data on file, last reported at $8.7 million in Q1 2026.

• Quarterly Non Operating Income rose 11.48% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.9 million (down 15.25% YoY) and the FY2025 annual result came in at $30.0 million, down 13.56% from the prior year.
• Non Operating Income steadied at $8.7 million in Q1 2026 per APGE's latest filing, from $8.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $10.3 million in Q2 2024 and bottomed at -$9.2 million in Q3 2022.
• The 5-year median for Non Operating Income is $6.7 million (2025), against an average of $5.2 million.
• The widest annual swing landed in 2023, when Non Operating Income soared 5791.3%; it then slumped 34.65% in 2025.
• Tracing APGE's Non Operating Income over 5 years: stood at $92000.0 in 2022, then soared by 5791.3% to $5.4 million in 2023, then soared by 60.17% to $8.7 million in 2024, then gained by 0.58% to $8.7 million in 2025, then advanced by 0.1% to $8.7 million in 2026.
• Per Business Quant, the three latest APGE Non Operating Income figures stand at $8.7 million (Q1 2026), $8.7 million (Q4 2025), and $6.3 million (Q3 2025).

Peer Comparison